Xvivo Perfusion AB (publ) (XVIPF)
OTCMKTS · Delayed Price · Currency is USD
20.54
0.00 (0.00%)
Aug 6, 2025, 8:00 PM EDT
Theseus Pharmaceuticals Market Cap
Xvivo Perfusion AB has a market cap or net worth of $621.52 million as of August 8, 2025. Its market cap has decreased by -59.22% in one year.
Market Cap
621.52M
Enterprise Value
599.35M
Revenue
86.54M
Ranking
n/a
PE Ratio
53.07
Stock Price
$20.54
Market Cap Chart
Since October 8, 2012, Xvivo Perfusion AB's market cap has increased from 56.07M to 621.52M, an increase of 1,008.46%. That is a compound annual growth rate of 20.60%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Aug 8, 2025 | 621.52M | -55.43% |
| Dec 30, 2024 | 1.39B | 35.52% |
| Dec 29, 2023 | 1.03B | 96.50% |
| Dec 30, 2022 | 523.72M | -42.34% |
| Dec 30, 2021 | 908.22M | -17.47% |
| Dec 30, 2020 | 1.10B | 126.83% |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2015 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Nika Pharmaceuticals | 972.93M |
| Veradigm | 806.69M |
| Tian'an Technology Group | 628.15M |
| Elite Pharmaceuticals | 625.65M |
| Glass House Brands | 497.52M |
| Northwest Biotherapeutics | 366.75M |
| American Oncology Network | 353.52M |
| CytoDyn | 322.85M |